Home › Funds › GSK plc › BNTX

GSK plc position in BNTX

BIONTECH SE · Health Care

GSK plc reported holding 668,526 shares of BNTX (BIONTECH SE) in its Q3 2026 13F filing — a position valued at US$65.7M, representing 13.22% of its reported portfolio and ranking #4 among its reported holdings. GSK plc has disclosed BNTX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)668.53K sh
Reported value held$65.72M
Portfolio Weight13.22%
First reportedQ4 2025
Last changeReduce
Updated2026-11-06

Last updated: 2026-11-06 · Source: SEC EDGAR Form 13F-HR

How GSK plc's BNTX position evolved

GSK plc first disclosed a stake in BNTX in Q4 2025 at 889,824 shares (US$84.7M). Across 4 filings, GSK plc increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 668,526 shares valued at US$65.7M — a reduction of -221,298 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q4 2025 889.82K $84.71M New
Q1 2026 889.82K $79.09M Hold
Q2 2026 889.82K $82.80M Hold
Q3 2026 668.53K $65.72M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BNTX and 13F data

BNTX (BIONTECH SE) is a Health Care company. 34 other funds we track also report a position in BNTX — the largest reported positions include FLOSSBACH VON STORCH SE (US$207.1M), Temasek Holdings (Private) Ltd (US$140.1M), Logos Global Management LP (US$94.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BNTX

All BNTX fund holders →

FAQ

How long has GSK plc held BNTX?

GSK plc has disclosed BNTX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is GSK plc's current position in BNTX?

As of Q3 2026, GSK plc holds 668.53K shares of BNTX (BIONTECH SE), valued at $65.72M, representing 13.22% of its reported portfolio and ranking #4.

Has GSK plc been buying or selling BNTX?

In the latest 13F filing (Q3 2026), GSK plc reduced its position in BNTX.

Which other funds hold BNTX?

Other major institutional holders of BNTX include FLOSSBACH VON STORCH SE, Temasek Holdings (Private) Ltd, Logos Global Management LP, among 34 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.